Shares of Aduro BioTech Inc (NASDAQ:ADRO) have been assigned a consensus rating of “Hold” from the ten brokerages that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $13.80.
Several research firms have commented on ADRO. Oppenheimer set a $10.00 price objective on shares of Aduro BioTech and gave the company a “buy” rating in a report on Tuesday, October 30th. BidaskClub downgraded shares of Aduro BioTech from a “hold” rating to a “sell” rating in a report on Wednesday, July 25th. Cowen reissued a “buy” rating on shares of Aduro BioTech in a report on Wednesday, October 31st. Bank of America dropped their price objective on shares of Aduro BioTech from $8.00 to $6.00 and set an “underperform” rating for the company in a report on Thursday, August 2nd. Finally, ValuEngine raised shares of Aduro BioTech from a “sell” rating to a “hold” rating in a report on Monday, October 22nd.
In related news, insider Natalie Sacks sold 4,504 shares of the stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $7.13, for a total value of $32,113.52. Following the completion of the transaction, the insider now owns 89,548 shares of the company’s stock, valued at approximately $638,477.24. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Blaine Templeman sold 10,262 shares of the stock in a transaction dated Monday, September 24th. The shares were sold at an average price of $5.81, for a total transaction of $59,622.22. Following the completion of the transaction, the insider now directly owns 131,119 shares of the company’s stock, valued at approximately $761,801.39. The disclosure for this sale can be found here. In the last ninety days, insiders sold 113,160 shares of company stock valued at $819,523. 5.00% of the stock is owned by insiders.
Several large investors have recently made changes to their positions in the stock. Alps Advisors Inc. lifted its holdings in shares of Aduro BioTech by 22.4% in the 3rd quarter. Alps Advisors Inc. now owns 139,907 shares of the biotechnology company’s stock valued at $1,028,000 after acquiring an additional 25,650 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of Aduro BioTech by 47.6% in the 2nd quarter. Northern Trust Corp now owns 695,702 shares of the biotechnology company’s stock valued at $4,871,000 after acquiring an additional 224,377 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Aduro BioTech by 19.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 220,247 shares of the biotechnology company’s stock valued at $1,541,000 after acquiring an additional 36,387 shares during the last quarter. Centaurus Financial Inc. bought a new position in shares of Aduro BioTech in the 2nd quarter valued at about $564,000. Finally, MetLife Investment Advisors LLC lifted its holdings in shares of Aduro BioTech by 70.6% in the 2nd quarter. MetLife Investment Advisors LLC now owns 31,799 shares of the biotechnology company’s stock valued at $223,000 after acquiring an additional 13,156 shares during the last quarter. 48.20% of the stock is owned by hedge funds and other institutional investors.
Shares of ADRO traded up $0.06 during midday trading on Friday, hitting $4.25. 1,605 shares of the company traded hands, compared to its average volume of 521,308. Aduro BioTech has a 52 week low of $3.69 and a 52 week high of $10.00. The company has a market capitalization of $370.02 million, a PE ratio of -3.04 and a beta of 2.70.
Aduro BioTech (NASDAQ:ADRO) last released its quarterly earnings data on Tuesday, October 30th. The biotechnology company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.02. Aduro BioTech had a negative net margin of 591.66% and a negative return on equity of 50.03%. The business had revenue of $3.06 million during the quarter, compared to the consensus estimate of $4.59 million. As a group, analysts forecast that Aduro BioTech will post -1.18 earnings per share for the current year.
About Aduro BioTech
Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.
Featured Article: Stop Order Uses For Individual Investors
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.